COVID-19 Update: Independent Conference Coverage of ECCMID 2023
May 05, 2023•37 min•Ep. 279
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
In this episode, Patrick W. G. Mallon, MB, BCh, PhD, FRACP, FRCPI, discusses new data on COVID-19 presented at ECCMID 2023, including:
- Treatment in special populations
- REDPINE: remdesivir in people with renal impairment hospitalized for COVID-19 pneumonia
- Remdesivir and readmission for COVID-19 in immunocompromised patients
- Molnupiravir vs nirmatrelvir plus ritonavir for COVID-19 with hematologic malignancy
- Management of patients with severe disease
- RECOVERY: higher-dose vs standard-dose corticosteroids for hospitalized patients with COVID-19
- Real-world study of tocilizumab vs baricitinib for severe COVID-19
- Novel antivirals
- Ensitrelvir
- Bemnifosbuvir
- Novel vaccines
- NB2155
- AZD2816/AZD1222
- qNIV/CoV2373
- GRT-R910
- NVX-CoV2373 in people with HIV
Faculty:
Patrick W. G. Mallon, MB, BCh, PhD, FRACP, FRCPI
Professor of Microbial Diseases
Centre for Experimental Pathogen Host Research
University College Dublin
Dublin, Ireland
Content based on an online CME/CE program supported by independent educational grants from Gilead Sciences, Inc. and Novavax.
Link to full program:
bit.ly/3niXGJ6
Link to downloadable slides:
bit.ly/3LUFejG
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
For the best experience, listen in Metacast app for iOS or Android